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Abstract
There is increasing evidence that type 2 diabetes
mellitus and glucose intolerance are a cause, not just
a consequence, of pancreatic cancer. We examined
whether other factors that characterize the insulin
resistance syndrome are also risk factors for pancreatic
cancer in a prospective cohort study of 631,172 men
and women (ages 45+ years) who received health
insurance from the Korean Medical Insurance Corpo-
ration. The biennial medical evaluations from 1992 to
1995 provided the baseline information for this study.
Relative risks (RR) were estimated using proportional
hazards models adjusted for age, sex, smoking, and
fasting serum glucose (after excluding the first 2 years
of follow-up). There were 2,194 incident cases of
pancreatic cancer diagnosed in the cohort over a
median follow-up of 12 years. There was no evidence
that pancreatic cancer risk was associated with total
cholesterol, systolic blood pressure, WBC count, or
body mass index. Abnormal levels of aspartate amino-
transferase and alanine aminotransferase were both
associated with a moderately increased risk of devel-
oping the disease (40+ versus <20; RR, 1.33; 95% CI,
1.14-1.55; Ptrend = 0.05 and RR, 1.34; 95% CI, 1.16-1.56;
P trend = 0.02, respectively). Excluding 6 years of follow-
up reduced this RR (95% CI) for aspartate aminotrans-
ferase to 1.22 (1.01-1.49), but even after excluding 10
years follow-up the RR (95% CI) for alanine amino-
transferase was unchanged [1.36 (1.01-1.83)]. Although
fasting serum glucose has been found previously to
be associated with pancreatic cancer risk in this
cohort, most other factors that characterize insulin
resistance syndrome were not associated with pancre-
atic cancer risk. The association with elevated liver
enzyme levels is a novel finding that warrants further
investigation. (Cancer Epidemiol Biomarkers Prev
2008;17(2):359–64)
Introduction
Insulin resistance syndrome, also known as the metabolic
syndrome, is a prediabetic state that produces compen-
satory hyperinsulinemia and is closely linked to the
development of both diabetes and cardiovascular disease
(1). Experimental studies have shown that insulin can
promote the growth of pancreatic cancer cells (2), and
there is increasing epidemiologic evidence that type 2
diabetes mellitus and glucose intolerance are a cause,
not just a consequence, of a portion of pancreatic cancers
(3-10). Obesity and central adiposity have also been
consistently associated with the disease (11-15), but
relatively little is known as to whether other, potentially
modifiable, risk factors that characterize the insulin
resistance syndrome, such as cholesterol levels and
blood pressure (16), are also associated with an increased
risk of pancreatic cancer.
The Korean Cancer Prevention Study is a long-term
prospective study of f1.3 million Koreans who were
insured by the Korean Medial Insurance Corporation,
which is now part of the National Health Insurance
Corporation. Elevated fasting serum glucose has been
found previously to be associated with an increased risk
of pancreatic cancer in this cohort, with levels of z126
mg/dL associated with a 1.5- to 2-fold increased risk of
disease compared with normal levels (17). In the current
study, we investigated in detail whether other factors that
characterize the insulin resistance syndrome are indepen-
dently related to the risk of developing pancreatic cancer.
Materials and Methods
Study Population. The study design and methods for
the Korean Cancer Prevention Study have been described
in detail previously (17, 18). Briefly, the cohort consists
of 1,329,525 Korean civil servants and their dependents
(846,907 men and 482,618 women) who received
health insurance from the Korean Medial Insurance
Corporation and who participated in at least one routine
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biennial medial evaluation between 1992 and 1995. The
first of these medical evaluations during this period
was considered to be the baseline visit for the study.
The population for the current study was restricted to
participants who were ages 45+ years at their baseline
visit (n = 703,947). Of these participants, 295,717 (42%)
were enrolled in 1992, 316,553 (45%) in 1993, 26,789 (4%)
in 1994, and 64,879 (9%) in 1995. Participants who
reported having atherosclerotic cardiovascular disease,
cancer, liver disease, or respiratory disease at or before
the baseline visit (n = 47,319) were excluded. In addition,
subjects with extremely low body mass index (BMI;
<16 kg/m2) or short stature (V1.3 m) were also excluded.
The first 2 years of follow-up were excluded to reduce
the possible effect of unidentified preexisting disease at
baseline. Therefore, the current analysis included 631,172
subjects.
Because the study involved routinely collected data,
consent was not specifically obtained. The study was
approved by the institutional review boards of Yonsei
University and the Johns Hopkins Bloomberg School of
Public Health.
Data Collection. The biennial medical examinations
were conducted by medical staff at local hospitals,
following a standard procedure. These routine examina-
tions include measurement of blood pressure (taken
while seated) and weight and height measurement
(wearing light clothing). Blood samples, taken after an
overnight fast, were used to determine total cholesterol,
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), and WBC count. Participants also complet-
ed a short lifestyle questionnaire. Quality-control
procedures were in accordance with the Korean Associ-
ation of Laboratory Quality Control.
Follow-up and Outcome Classification. Participants
were followed from study entry (1992-1995) until first
pancreatic cancer diagnosis, death, or the end of the
follow-up period (December 31, 2005). Outcomes of
cancer incidence were based on national cancer registry
data and hospitalization records. Although Korea has a
national cancer registry, it did not cover the entire
population during the period of follow-up, so claims
data for the Korean National Health Insurance Corpora-
tion generated from hospital admission files were also
used to identify incident cases of pancreatic cancer. Since
2003, this system has also become the main data source
for the Korean Central Cancer Registry. An incident
cancer case was coded as occurring either on a positive
report from the national cancer registry or on a hospital
admission for a cancer diagnosis. Outcomes for mortality
were ascertained from the causes of death recorded
on death certificates. Computerized death certificate
searches from the National Statistical Office were done
using the national identification number assigned at
birth. Trained abstractors coded causes of death accord-
ing to the International Classification of Diseases, Tenth
Revision .
Statistical Analysis. We estimated relative risks (RR)
and 95% confidence intervals (95% CI) for pancreatic
cancer for the baseline risk factors (19) using relative
hazards calculated using the Cox proportional hazards
model. BMI was calculated as weight divided by height
squared, and the normal range was based on the Asian
specific cut-point (<18.5, 18.5-22.9, 23.0-27.4, and 27.5+
kg/m2; ref. 20). Subjects were categorized according to
sex-specific quintiles of height, weight, and WBC count
and according to categories of ALT, AST, systolic blood
pressure (SBP), and total cholesterol that were defined
using standard clinical cut-points. All analyses were
adjusted for age at enrollment, gender, smoking status
[never, past, current (<10, 10-19, and 20+ cigarettes per
day)], BMI, and fasting serum glucose levels. Trend tests
were conducted using the category medians as the
scores. All analyses were conducted using SAS version
8.0 (21).
Results
The cohort included 631,172 participants ages 45+ years
at study entry who were followed up for a total of
7,338,797 person-years with a median follow-up of
12.0 years. The median age at baseline was 54 years for
males and 56 years for females. Males were much more
likely to be current smokers (54.8%) than females (6.2%)
and also more likely to drink alcohol (71.3% and 13.4%,
respectively; Table 1). During the follow-up period,
there were a total of 2,194 incident cases or deaths from
pancreatic cancer. Of these, 1,944 were ascertained
through the cancer registry or hospital admissions
(incident cases) and 250 were ascertained only from
death certificates (1,422 of the incident cases were also
subsequently reported on death certificates). Median age
Table 1. Baseline characteristics of the subjects in the Korean Cancer Prevention Study (ages 45+ years)
Variable Men Women
n Mean (SD), median n Mean (SD), median
Age (y) 358,474 54.8 (7.6), 54.0 272,698 57.0 (8.6), 56.0
BMI (kg/m2) 358,474 23.3 (2.6), 23.2 272,698 24.0 (3.1), 23.8
Fasting serum glucose (mg/dL) 358,244 96.4 (30.0), 91.0 272,464 93.5 (27.6), 89.0
Total cholesterol (mg/dL) 358,243 195.6 (38.8), 193.0 272,470 203.1 (39.8), 200.0
SBP (mm Hg) 358,411 128.5 (18.1), 130.0 272,587 126.4 (20.6), 120.0
ALT 358,220 25.4 (19.0), 21.0 272,444 20.7 (12.0), 18.0
% %
Current smoking 358,474 54.8 272,698 6.2
Alcohol drinking 358,474 71.3 272,698 13.4
Family history of diabetes 288,922 4.7 212,232 6.3
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at diagnosis/death was 57 years for males (n = 1,505) and
61 years for females (n = 689). Analyses were initially
done separately for pancreatic cancer incidence and
mortality. However, the results were generally similar
because the high fatality rate of pancreatic cancer meant
that mortality was a close approximation to incidence;
therefore, we report only the results for the combined
outcome.
In this cohort, elevated fasting serum glucose levels
were strongly associated with several factors, including
BMI, total cholesterol, blood pressure, and ALT (P < 0.001;
Table 2). Current smokers, alcohol drinkers, and those
with a family history of diabetes were also more likely to
have elevated fasting serum glucose levels (P < 0.001).
There was no clear relationship between total choles-
terol level, SBP, or WBC count and pancreatic cancer
risk. However, elevated levels of AST and ALT were
associated with a moderately increased risk of develop-
ing the disease. For abnormal (40+) versus normal (<20)
liver function levels, the RR (95% CI) for pancreatic
cancer was 1.33 (1.14-1.55) for AST and 1.34 (1.16-1.56)
for ALT (P trend = 0.05 and 0.02, respectively; Table 3).
To assess whether this association could be due to
reverse causality, we examined the effect of excluding
increasing periods of follow-up (4, 6, 8, and 10 years;
Table 4). There was a small reduction in the RR (95% CI)
for AST when 6 years of follow-up were excluded [1.22
(1.01-1.49); P trend = 0.04 for 40+ versus 20]. For ALT,
the patterns of risk were largely unchanged even after
exclusion of the first 10 years of follow-up, although
the reduction in the number of cases decreased the
power. Tests for interaction between AST or ALT levels
and follow-up time were not statistically significant
(P = 0.99 and 0.93, respectively, treating both variables
as continuous).
ALT and AST levels in this cohort were highly
correlated (r = 0.73) and both were associated with
alcohol consumption and hepatitis B virus infection and
in those who were nondrinkers with obesity and elevated
fasting serum glucose levels (data not shown). However,
neither alcohol consumption (RR, 1.06; 95% CI, 0.83-1.34
for 50+ versus 0 g/d; P trend = 0.2) nor hepatitis B surface
antigen status was associated with pancreatic cancer risk
(RR, 1.13; 95% CI, 0.84-1.52). In the subset of subjects who
were not hepatitis B surface antigen carriers and who
reported that they did not drink alcohol, the RRs (95%
CIs) were higher for both abnormal (40+) ALT [1.62 (0.98-
2.68)] and AST [1.97 (1.13-3.45)]. Hepatitis B surface
antigen status information was only available for a subset
Table 3. RR (95% CI) of pancreatic cancer according to
available clinical measurements
Cases RR (95% CI)
Adjusted* Adjusted
c
Total cholesterol (mg/dL)
<200 1,232 1.0 1.0
200-239 647 0.91 (0.83-1.01) 0.91 (0.82-1.00)
240+ 311 1.00 (0.88-1.13) 0.97 (0.85-1.10)
P trend 0.98 0.77
SBP (mm Hg)
<120 530 1.0 1.0
120-129 487 0.97 (0.86-1.10) 0.97 (0.86-1.10)
130-139 467 1.01 (0.89-1.14) 1.01 (0.89-1.14)
140+ 710 0.99 (0.88-1.11) 0.98 (0.88-1.10)
P trend 0.91 0.98
WBC
b
(cells/L)
1st 226 1.0 1.0
2nd 252 1.07 (0.92-1.24) 1.08 (0.93-1.26)
3rd 213 0.97 (0.83-1.14) 0.98 (0.83-1.14)
4th 265 1.12 (0.97-1.30) 1.11 (0.96-1.29)
5th 262 1.08 (0.93-1.26) 1.05 (0.91-1.22)
P trend 0.33 0.58
AST
<20 578 1.0 1.0
20-30 976 0.99 (0.89-1.10) 1.00 (0.90-1.11)
30-40 412 1.18 (1.04-1.34) 1.19 (1.05-1.35)
40+ 224 1.34 (1.15-1.56) 1.33 (1.14-1.55)
P trend 0.06 0.05
ALT
<20 975 1.0 1.0
20-30 708 1.05 (0.96-1.16) 1.06 (0.96-1.16)
30-40 273 1.19 (1.04-1.36) 1.19 (1.04-1.36)
40+ 234 1.36 (1.18-1.57) 1.34 (1.16-1.56)
P trend 0.02 0.02
*Adjusted for age and gender.
cAdjusted for age, gender, body mass index, smoking, and fasting serum
glucose levels.
bSex-specific quintiles WBC: male (<5,700, 5,700-6,599, 6,600-7,399, 7,400-
8,499, and z8,500) and female (<5,200, 5,200-5,999, 6,000-6,699, 6,700-
7,699, and z7,700).
Table 2. Baseline characteristics according to baseline levels of fasting serum glucose
Variable Fasting serum glucose (mg/dL)
<90 90-125 126+ P*
n Mean (SD) n Mean (SD) N Mean (SD)
Age (y) 308,380 55.5 (8.1) 282,528 55.9 (8.1) 40,264 57.3 (8.0) <0.0001
BMI (kg/m2) 308,380 23.4 (2.8) 282,528 23.7 (2.9) 40,264 24.0 (2.9) <0.0001
Total cholesterol (mg/dL) 307,928 195.3 (37.7) 282,525 201.1 (39.4) 40,260 209.7 (47.9) <0.0001
SBP (mm Hg) 308,304 125.7 (18.7) 282,443 128.9 (19.5) 40,251 132.8 (20.4) <0.0001
ALT 307,908 22.1 (14.8) 282,497 24.1 (16.8) 40,259 28.1 (23.9) <0.0001
% % %
Current smoking 308,380 33.1 282,528 34.1 40,264 37.0 <0.0001
Alcohol drinking 308,380 43.2 282,528 49.0 40,264 51.0 <0.0001
Family history of diabetes 245,298 4.4 223,759 5.2 32,097 14.6 <0.0001
*Tested using ANOVA for continuous variables and m2 test for categorical variables.
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of the study population (32%); hence, the power of this
analysis was somewhat limited.
There was no clear relationship between increased
height, weight, or BMI and the risk of developing
pancreatic cancer (Table 5). Neither was there evidence
that a family history of diabetes was associated with an
increased risk of pancreatic cancer (RR, 1.04; 95% CI,
0.84-1.29).
To evaluate potential effect modification, stratified
analyses were conducted for men and women separately.
There were no evidence of statistically significant
heterogeneity between males and females for any of the
risk factors considered (P > 0.05). In general, the results
were similar to those for all subjects combined, but there
was evidence of a weak association between elevated
weight and pancreatic cancer risk in females, which
was not observed for males (RR, 1.19; 95% CI, 0.93-1.51;
P trend = 0.01 versus RR, 0.97; 95% CI, 0.82-1.14; Ptrend = 0.9
for the top compared with the bottom quintile).
We also repeated all of the analyses in the subgroups
of never smokers and nondiabetics (defined as no self-
reported diabetes at baseline and/or fasting serum
glucose <140 mg/dL) to assess whether there may have
been residual confounding by these factors. In the
analysis restricted to never smokers, there was also some
evidence of an association with increasing weight (RR,
1.24; 95% CI, 0.99-1.55 for the top compared with the
bottom quintiles; P trend = 0.04). There were no material
differences observed when the analyses were restricted
to nondiabetics, which was consistent with the observa-
tion that adjustment for fasting serum glucose levels did
not modify any of the associations.
Discussion
In this large, prospective study, pancreatic cancer risk
was associated with abnormal ALT and AST levels.
Despite the fact that cholesterol, SBP, and BMI were
strongly associated with fasting serum glucose levels,
there was no evidence that these factors were associated
with pancreatic cancer risk.
As far as we are aware, this is the first study to
examine the association between liver enzymes and
pancreatic cancer risk. The moderate association with
ALT was not altered materially when increasing lag
periods were considered, which suggests that the
association was not due to reverse causality. The asso-
ciation with AST was weakened slightly when 6+ years
of follow-up were excluded. Factors that were related
to elevated ALT and AST in this population were fasting
serum glucose, obesity, alcohol consumption, and hepa-
titis B virus infection. However, most of these factors
were not related to pancreatic cancer in this cohort and
adjustment for fasting serum glucose levels did not
materially alter the estimated RRs. Liver enzymes are not
Table 5. RR (95% CI) of pancreatic cancer according to
anthropometric factors
Cases RR (95% CI)
Adjusted* Adjusted
c
Height (cm)
b
1st 414 1.0 1.0
2nd 355 0.93 (0.80-1.07) 0.92 (0.80-1.07)
3rd 497 1.13 (0.99-1.29) 1.12 (0.98-1.28)
4th 443 1.03 (0.89-1.18) 1.02 (0.89-1.18)
5th 485 1.09 (0.94-1.25) 1.09 (0.94-1.25)
P trend 0.33 0.33
Weight (kg)x
1st 456 1.0 1.0
2nd 397 0.92 (0.81-1.06) 0.93 (0.81-1.07)
3rd 486 1.04 (0.92-1.19) 1.07 (0.93-1.22)
4th 400 0.99 (0.86-1.14) 1.01 (0.88-1.17)
5th 455 1.01 (0.88-1.16) 1.04 (0.90-1.19)
P trend 0.59 0.42
BMI (kg/m2)
<18.5 66 0.76 (0.59-0.98) 0.78 (0.60-1.00)
18.5-22.9 963 1.0 (Reference) 1.0 (Reference)
23.0-27.4 1,008 0.98 (0.90-1.08) 0.98 (0.89-1.07)
27.5+ 157 0.97 (0.82-1.15) 0.95 (0.80-1.12)
P trend 0.30 0.38
*Adjusted for age and gender.
cAdjusted for age, gender, smoking, and fasting serum glucose levels.
bSex-specific quintiles height: male (<162, 162-164.9, 165-167.9, 168-170.9,
and z171) and female (<148, 148-151.9, 152-154.9, 155-157.9, and z158).
xSex-specific quintiles weight: male (<57, 57-61.9, 62-66.4, 66.5-71.9, and
z72) and female (<49, 49-53.9, 54-57.9, 58-62.9, z63).
Table 4. RR (95% CI) of pancreatic cancer according to ALT and AST levels excluding 2, 4, 6, 8, and 10 years of
follow-up
No. years of follow-up excluded
2 4 6 8 10
Cases RR* (95% CI) Cases RR* (95% CI) Cases RR* (95% CI) Cases RR* (95% CI) Cases RR* (95% CI)
AST
<20 578 1.00 494 1.00 392 1.00 276 1.00 137 1.00
20-30 976 1.00 (0.90-1.11) 847 1.02 (0.91-1.14) 669 1.02 (0.90-1.16) 460 1.00 (0.86-1.16) 245 1.09 (0.88-1.34)
30-40 412 1.19 (1.05-1.35) 336 1.14 (0.99-1.31) 258 1.11 (0.95-1.31) 175 1.08 (0.89-1.31) 832 1.04 (0.79-1.37)
40+ 224 1.33 (1.14-1.55) 195 1.36 (1.15-1.61) 136 1.22 (1.01-1.49) 89 1.16 (0.91-1.48) 45 1.21 (0.86-1.70)
P trend 0.05 0.06 0.04 0.05 0.17
ALT
<20 975 1.00 845 1.00 662 1.00 435 1.00 223 1.00
20-30 708 1.06 (0.96-1.16) 602 1.03 (0.92-1.14) 465 1.01 (0.89-1.13) 332 1.08 (0.94-1.25) 166 1.01 (0.83-1.24)
30-40 273 1.19 (1.04-1.36) 225 1.12 (0.96-1.30) 174 1.09 (0.92-1.29) 126 1.19 (0.97-1.45) 63 1.10 (0.83-1.46)
40+ 234 1.34 (1.16-1.56) 200 1.31 (1.12-1.54) 154 1.28 (1.07-1.53) 107 1.34 (1.08-1.67) 58 1.36 (1.01-1.83)
P trend 200 0.02 0.06 0.09 0.01 0.10
*Adjusted for age, gender, body mass index, smoking, and fasting serum glucose levels.
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formally classified as components of the insulin resis-
tance syndrome, but there is increasing evidence that
they are also associated with insulin resistance (22-24). In
addition to the association with insulin resistance, these
enzymes are elevated in individuals with pancreatitis, a
risk factor for pancreatic cancer, and among those with
bile duct obstruction. It is possible that these enzymes
may be elevated in response to preneoplastic changes in
the pancreas. For example, chronic pancreatitis-like
changes have been observed in conjunction with pancre-
atic intraepithelial neoplasia lesions in patients
at high risk of developing pancreatic cancer (25), and
pancreatic intraepithelial neoplasia lesions are more
frequent in individuals with chronic pancreatitis (26).
As well as examining this association in other study
populations, studies are needed to determine possible
causes of the abnormal liver function before the
development of invasive pancreatic cancer.
Obesity, defined as BMI >27.5 kg/m2, was not related
to pancreatic cancer risk in this cohort. Most definitions
of the insulin resistance syndrome are based on measures
of central adiposity, such as waist circumference, rather
than the overall obesity measure of BMI (16). Unfortu-
nately, neither waist nor hip circumference measures
were available in the current study. Several previous
studies, including a pooled analysis of Asian cohorts,
have found that there may be a stronger association
between pancreatic cancer risk and waist circumference
than with BMI (12-15).
Several other studies have also reported null associa-
tions between blood pressure, cholesterol, and the risk
of pancreatic cancer (15, 27, 28). One cohort study of
hypertensive patients reported an increased risk of
developing pancreatic cancer for women compared with
the risk in the general population (29).
This is one of the largest prospective studies of
pancreatic cancer to date. The availability of various
clinical measures, including cholesterol, blood pressure,
and liver enzyme levels, enabled the evaluation of
several novel risk factors for a disease with few
established causes. Adjustment for fasting serum glucose
levels, as opposed to self-reported diabetes, is an
advantage in that the potential for residual confounding
with respect to preclinical diabetes is reduced and there
is unlikely to be nondifferential misclassification of
diabetes status. It also allowed us to assess whether
any other factors that were associated with fasting serum
glucose levels were independently associated with
pancreatic cancer risk. A potential limitation of this
study is that there could be additional assay variability
because all the measurements were collected for routine
clinical, not for research, purposes and measurements for
the entire cohort were only available at baseline.
However, quality-control procedures were followed,
which helped to ensure reliability of the assays.
Furthermore, the use of clinical samples makes these
findings readily generalizable to the clinic setting. The
large size of the cohort meant that it was not possible to
conduct active follow-up; hence, information on emigra-
tion was not available and we were unable to assess the
losses to follow-up. However, emigration is thought to be
limited in this population and, if present, is nondiffer-
ential with respect to pancreatic cancer.
The disease incidence rates reported in a previous
study of this cohort of f20 per 100,000 were of similar
magnitude to the rates for South Korea reported in
Cancer Incidence in Five Continents (30). Microscopic
confirmation of pancreatic cancer was not available
and it is possible that there was some misclassification
of the outcome (31). One recent study found that the
association with BMI was limited to microscopically
confirmed cases of pancreatic cancer (32), which suggests
that misclassification was nondifferential. Whether
misclassification would be nondifferential in other study
populations is difficult to predict and could vary
according to the risk factor of interest and the diseases
that were misclassified as pancreatic cancer.
Although fasting serum glucose has been found
previously to be associated with pancreatic cancer risk
in this cohort, most other factors that characterize
insulin resistance syndrome were not associated with
pancreatic cancer risk. The association with elevated liver
enzyme levels is a novel finding that warrants further
investigation.
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